What is the primary driver behind the significant increase in revenues?

The substantial increase in revenues, particularly the 24% rise in the second quarter and 35% in the first six months of 2004, is primarily attributed to the full inclusion of Pharmacia's financial results following its acquisition in April 2003. Additionally, favorable foreign exchange rates contributed to the revenue growth.

How has net income and earnings per share changed compared to the previous year?

Net income dramatically improved, shifting from a net loss of $3.59 billion in the second quarter of 2003 to a net income of $2.86 billion in the second quarter of 2004. This turnaround is largely due to the absence of significant one-time charges, such as the merger-related in-process R&D, that impacted the prior year's results. Correspondingly, diluted earnings per share improved from a loss of $0.48 in Q2 2003 to $0.38 in Q2 2004.

What is the company doing with its business portfolio?

Pfizer is actively managing its portfolio by divesting businesses and product lines that do not fit its strategic plan. In the first six months of 2004, the company decided to sell or agreed to sell its in-vitro allergy and autoimmune diagnostics testing business, its surgical ophthalmic business, certain non-core consumer product lines in Europe, and certain European generic pharmaceutical businesses. These are being reported as discontinued operations.

How is Pfizer's financial health and liquidity?

Pfizer maintains a strong financial position. As of June 27, 2004, cash and cash equivalents and short-term investments totaled $17.98 billion. The company generated $5.17 billion in net cash from continuing operating activities for the first six months of 2004. Working capital also increased significantly, indicating a healthy liquidity position. The company also benefits from strong credit ratings, providing access to favorable financing rates.

PFE 10-Q Quarterly Report Q2 FY2004 — Revenue, Net Income, EPS

Summary

Pfizer Inc. (PFE) reported strong revenue growth of 24% for the second quarter of 2004 and 35% for the first six months of 2004, largely driven by the full inclusion of Pharmacia's results following its acquisition in April 2003 and favorable foreign exchange rates. Net income for the quarter was $2.86 billion, a significant turnaround from a net loss of $3.59 billion in the prior year's quarter, reflecting the impact of substantial one-time charges in 2003 related to the Pharmacia acquisition, particularly merger-related in-process R&D. Diluted EPS also saw a substantial improvement, reaching $0.38 compared to a loss of $0.48 in the prior year. The company is actively managing its portfolio, divesting non-core assets, including diagnostic and surgical ophthalmic businesses, while simultaneously investing in research and development. The financial position remains solid, with a significant increase in cash and cash equivalents and short-term investments, and a healthy working capital position. Pfizer also continues its share repurchase program and dividend payments, demonstrating a commitment to shareholder returns.

Key Highlights

1Significant revenue growth (24% in Q2, 35% YTD) primarily due to the full inclusion of Pharmacia's results and favorable currency movements.
2Turnaround in net income, reporting $2.86 billion for Q2 2004 compared to a $3.59 billion loss in Q2 2003, due to the absence of large 2003 merger-related charges.
3Diluted EPS improved to $0.38 from a loss of $0.48 in the prior year's comparable quarter.
4Active portfolio management with planned divestitures of non-core businesses, including diagnostics and surgical ophthalmic divisions.
5Robust cash flow generation from operations ($5.17 billion YTD) and strong liquidity, with cash and short-term investments totaling $17.98 billion.
6Continued commitment to shareholder returns through share repurchases ($2.3 billion YTD) and dividend payments ($0.17 per share for Q2).
7Strategic acquisition of Esperion Therapeutics for $1.3 billion to bolster its cardiovascular disease pipeline.

PFIZER INC Quarterly Report for Q2 Ended Jun 27, 2004

Summary

Key Highlights

Frequently Asked Questions